Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Malaz AbuTarif"'
Autor:
Ying Hong, Tomoko Ishizuka, Akiko Watanabe, Masaya Tachibana, Mark Lee, Hitoshi Ishizuka, Frank LaCreta, Malaz Abutarif
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2220-2230 (2021)
Abstract Milademetan is a small‐molecule inhibitor of murine double minute 2 (MDM2) that is in clinical development for advanced solid tumors and hematological cancers, including liposarcoma and acute myeloid leukemia. Milademetan is a CYP3A and P
Externí odkaz:
https://doaj.org/article/e9cdb914f78a466084a85f5aa18226a3
Autor:
Malaz Abutarif, David Jaworowicz, Alexander E. Perl, Jill Fiedler-Kelly, Youngsook Choi, Nigel H. Russell, Siddhartha Ganguly, Alwin Krämer, Ophelia Yin, Mark J. Levis, Samer K. Khaled, Dongwoo Kang, Giovanni Martinelli, Jorge E. Cortes, Elizabeth Ludwig, Hannah Huang
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose This analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia’s formula (QTcF) in patients with relapsed/refractory acute myeloid leukemia (AML) tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f76e3afa26bf8e134e7d791e5ced06e
https://doi.org/10.1007/s00280-020-04204-y
https://doi.org/10.1007/s00280-020-04204-y
Autor:
Russ Wada, Ophelia Yin, Malaz Abutarif, Frank LaCreta, Seiko Endo, Kazutaka Yoshihara, Yuan Xiong, Tushar Garimella
Publikováno v:
Clinical Pharmacology and Therapeutics
Trastuzumab deruxtecan (DS-8201) is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate with a novel enzyme-cleavable linker, a topoisomerase I inhibitor payload, and a drug-to-antibody ratio of ≈ 8. We have characte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::579aefc1dab70ff9fbaf10554ef35562
http://europepmc.org/articles/PMC8246728
http://europepmc.org/articles/PMC8246728
Autor:
Yasong Lu, Shinji Shimizu, Ryoko Sawamura, Naoyuki Tajima, Ling He, Mark Lee, Malaz Abutarif, Rong Shi
Publikováno v:
Journal of clinical pharmacologyReferences.
Patritumab deruxtecan is an antibody-drug conjugate consisting of a fully human monoclonal antibody against human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. As
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c32d5b6984570f982599a5c233af4f9a
https://pubmed.ncbi.nlm.nih.gov/36053771
https://pubmed.ncbi.nlm.nih.gov/36053771
Autor:
Jeanne Mendell, Ophelia Yin, Mark J. Levis, Dongwoo Kang, Youngsook Choi, Siddhartha Ganguly, Malaz Abutarif, Giovanni Martinelli, Elizabeth Ludwig, Hannah Huang, Samer K. Khaled, David Jaworowicz, Jorge E. Cortes, Nigel H. Russell, Alwin Krämer, Alexander E. Perl, Jill Fiedler-Kelly
Publikováno v:
Journal of Clinical Pharmacology
Quizartinib is an FMS‐like tyrosine kinase 3 (FLT3) inhibitor that has shown robust clinical activity in patients with FLT3‐internal tandem duplication–mutated relapsed/refractory acute myeloid leukemia (AML). This analysis evaluated the popula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3ccb48d5e3463d7b16dc6a91415e751
http://europepmc.org/articles/PMC7689835
http://europepmc.org/articles/PMC7689835
Autor:
Yi-Ting Chang, Rahul Bhatnagar, K. Sims, Megan Wind-Rotolo, Frank LaCreta, Tushar Garimella, Elsa Myers, Timothy Eley, Xiaolu Tao, Jignasa Rana, Malaz AbuTarif
Publikováno v:
Drugs in R&D
Background A fixed-dose combination of daclatasvir (DCV; hepatitis C virus NS5A inhibitor), asunaprevir (ASV; non-structural protein 3 inhibitor), and beclabuvir (BCV; non-structural protein 5B inhibitor) is approved in Japan for hepatitis C virus ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1249e9be0f3be113ec1866a4edf0a673
http://europepmc.org/articles/PMC5833906
http://europepmc.org/articles/PMC5833906
Autor:
Holly Soares, Chunlin Chen, Phyllis Chan, Shu-Pang Huang, Glenn D. Rosen, Nancy Zhang, Malaz AbuTarif, Leon Bax
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 6:695-704
Recently, the US Food and Drug Administration (FDA) approved the first two drugs (pirfenidone and nintedanib) indicated for the treatment of idiopathic pulmonary fibrosis (IPF). The purpose of this analysis was to leverage publicly available data to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73d590cff0f9b2bde1ebd3055867788e
https://doi.org/10.1002/psp4.12227
https://doi.org/10.1002/psp4.12227
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 6:596-603
The 6-minute walk test (6MWT) is used as a clinical endpoint to evaluate drug efficacy in Duchenne Muscular Dystrophy (DMD) trials. A model was developed using digitized 6MWT data that estimated two slopes and two intercepts to characterize 6MWT impr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c073953f5d03896578b0f51b2c7c8eb
https://doi.org/10.1002/psp4.12220
https://doi.org/10.1002/psp4.12220
Autor:
Takayo Ueno, Li Zhu, Mayu Osawa, Malaz AbuTarif, Marc Bifano, Richard Bertz, Phyllis Chan, Tushar Garimella, Timothy Eley, Hanbin Li, Eric Hughes
Publikováno v:
Clinical Pharmacokinetics. 56:1173-1183
Daclatasvir is a potent, pangenotypic once-daily hepatitis C virus (HCV) NS5A inhibitor that is approved for the treatment of chronic HCV infection. The objective of this analysis was to characterize the pharmacokinetics of daclatasvir in subjects wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::432fd531b8b60b1b104b718b1feac0fb
https://doi.org/10.1007/s40262-016-0504-2
https://doi.org/10.1007/s40262-016-0504-2
Autor:
John Morrison, Kenneth M. Boy, Alan S. Robertson, Malaz AbuTarif, Jeremy H. Toyn, Valerie Guss, Xiaoliang Zhuo, Maciej Gasior, James E. Grace, Cong Wei, Jun-Sheng Wang, Quan Hong, Joseph Raybon, Lynda S. Cook, Nina Hoque, Richard E. Olson, Wendy Clarke, Rex Denton, Lorin A. Thompson, Francis Sweeney, Flora Berisha, Jere E. Meredith, Dieter M. Drexler, Holly Soares, Kimberly A. Lentz, Charlie F. Albright, Ramesh Padmanabha, Michael J. Furlong, John E. Macor, Michael K. Ahlijanian, Dmitry Zuev, Kimberly Snow
Publikováno v:
The Journal of Pharmacology and Experimental Therapeutics
The amyloid-β peptide (Aβ)-in particular, the 42-amino acid form, Aβ1-42-is thought to play a key role in the pathogenesis of Alzheimer's disease (AD). Thus, several therapeutic modalities aiming to inhibit Aβ synthesis or increase the clearance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c27817650721b910af7d1d2e922680b
https://doi.org/10.1124/jpet.116.232249
https://doi.org/10.1124/jpet.116.232249